Gilead Sciences Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.96-0.21 (-0.27%)
As of 3:28 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close78.17
Bid77.89 x 700
Ask77.90 x 1000
Day's Range77.66 - 78.39
52wk Range77.63 - 113.31
1y Target EstN/A
Market Cap102.88B
P/E Ratio (ttm)6.84
Avg Vol (3m)10,240,462
Dividend & Yield1.88 (2.36%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals22 minutes ago

    University of Minnesota sues Gilead over $20 billion Hepatitis C drug business

    The University of Minnesota is suing Gilead Sciences Inc., alleging the pharmaceuticals company's lucrative Hepatitis C drugs infringe on a university patent. In a lawsuit filed in Minnesota's U.S. District Court Monday, the university claimed its intellectual property covers Gilead products that contain the drug sofosbuvir, including those sold under the brand names Sovaldi and Harvoni. The state university system said it brought its patent concerns to Gilead (GILD) in August 2015, but the company continued its alleged infringement.

  • Market Realist58 minutes ago

    Strong Growth Projected for UTHR’s Hypertension Drugs

    United Therapeutics has projected that in 2016, its trepostinil pulmonary arterial hypertension drugs will benefit from patients' shifting away from Uptravi.

  • Market Realist58 minutes ago

    Why UTHR Trades at Lower Multiples Compared to Its Peers

    On August 26, 2016, United Therapeutics (UTHR) was trading at a forward PE (price-to-earnings) ratio of ~7.7x.